These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 20392231

  • 1. Bone turnover across the menopause transition : The role of gonadal inhibins.
    Nicks KM, Fowler TW, Akel NS, Perrien DS, Suva LJ, Gaddy D.
    Ann N Y Acad Sci; 2010 Mar; 1192():153-60. PubMed ID: 20392231
    [Abstract] [Full Text] [Related]

  • 2. Inhibin and the regulation of bone mass.
    Gaddy D.
    Curr Osteoporos Rep; 2008 Jun; 6(2):51-6. PubMed ID: 18778563
    [Abstract] [Full Text] [Related]

  • 3. Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone.
    Perrien DS, Achenbach SJ, Bledsoe SE, Walser B, Suva LJ, Khosla S, Gaddy D.
    J Clin Endocrinol Metab; 2006 May; 91(5):1848-54. PubMed ID: 16449331
    [Abstract] [Full Text] [Related]

  • 4. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures.
    Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC.
    Endocrinology; 2002 Jan; 143(1):74-83. PubMed ID: 11751595
    [Abstract] [Full Text] [Related]

  • 5. Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.
    Nicks KM, Perrien DS, Akel NS, Suva LJ, Gaddy D.
    Mol Cell Endocrinol; 2009 Oct 30; 310(1-2):11-20. PubMed ID: 19615428
    [Abstract] [Full Text] [Related]

  • 6. Inhibin A is an endocrine stimulator of bone mass and strength.
    Perrien DS, Akel NS, Edwards PK, Carver AA, Bendre MS, Swain FL, Skinner RA, Hogue WR, Nicks KM, Pierson TM, Suva LJ, Gaddy D.
    Endocrinology; 2007 Apr 30; 148(4):1654-65. PubMed ID: 17194739
    [Abstract] [Full Text] [Related]

  • 7. Inhibins differentially antagonize activin and bone morphogenetic protein action in a mouse adrenocortical cell line.
    Farnworth PG, Stanton PG, Wang Y, Escalona R, Findlay JK, Ooi GT.
    Endocrinology; 2006 Jul 30; 147(7):3462-71. PubMed ID: 16601134
    [Abstract] [Full Text] [Related]

  • 8. Bone turnover markers and bone density across the menopausal transition.
    Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, Wark JD.
    J Clin Endocrinol Metab; 1996 Sep 30; 81(9):3366-71. PubMed ID: 8784098
    [Abstract] [Full Text] [Related]

  • 9. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2.
    Koide M, Murase Y, Yamato K, Noguchi T, Okahashi N, Nishihara T.
    Biochem Biophys Res Commun; 1999 May 27; 259(1):97-102. PubMed ID: 10334922
    [Abstract] [Full Text] [Related]

  • 10. The menopausal transition--endocrinology.
    Burger H.
    J Sex Med; 2008 Oct 27; 5(10):2266-73. PubMed ID: 18624962
    [Abstract] [Full Text] [Related]

  • 11. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition.
    Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, Harlow S, Randolph JF.
    J Clin Endocrinol Metab; 2008 Sep 27; 93(9):3478-83. PubMed ID: 18593767
    [Abstract] [Full Text] [Related]

  • 12. Concerted action of Smad and CREB-binding protein regulates bone morphogenetic protein-2-stimulated osteoblastic colony-stimulating factor-1 expression.
    Ghosh-Choudhury N, Singha PK, Woodruff K, St Clair P, Bsoul S, Werner SL, Choudhury GG.
    J Biol Chem; 2006 Jul 21; 281(29):20160-70. PubMed ID: 16707491
    [Abstract] [Full Text] [Related]

  • 13. Bone turnover alterations across the menopausal transition in south-eastern Chinese women [corrected].
    Ma L, Song Y, Li C, Wang E, Zheng D, Qu F, Zhou J.
    Climacteric; 2016 Aug 21; 19(4):400-5. PubMed ID: 27147201
    [Abstract] [Full Text] [Related]

  • 14. Ovarian aging and bone metabolism in menstruating women aged 35-50 years.
    Vural F, Vural B, Yucesoy I, Badur S.
    Maturitas; 2005 Oct 16; 52(2):147-53. PubMed ID: 16186077
    [Abstract] [Full Text] [Related]

  • 15. Inhibin α-subunit inhibits BMP9-induced osteogenic differentiation through blocking BMP/Smad signal and activating NF-κB signal in mesenchymal stem cells.
    Huang M, Cheng YL, Zeng JT, Su XY, Liu H.
    J Cell Biochem; 2018 Nov 16; 119(10):8271-8281. PubMed ID: 29923343
    [Abstract] [Full Text] [Related]

  • 16. The endocrinology of the menopause.
    Burger HG.
    J Steroid Biochem Mol Biol; 1999 Nov 16; 69(1-6):31-5. PubMed ID: 10418978
    [Abstract] [Full Text] [Related]

  • 17. Inhibin is an antagonist of bone morphogenetic protein signaling.
    Wiater E, Vale W.
    J Biol Chem; 2003 Mar 07; 278(10):7934-41. PubMed ID: 12493742
    [Abstract] [Full Text] [Related]

  • 18. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X, Xing J, Long CL, Peng Q, Humphrey MB.
    J Bone Miner Res; 2017 Nov 07; 32(11):2207-2218. PubMed ID: 28650106
    [Abstract] [Full Text] [Related]

  • 19. Regulatory mechanisms of osteoblast and osteoclast differentiation.
    Katagiri T, Takahashi N.
    Oral Dis; 2002 May 07; 8(3):147-59. PubMed ID: 12108759
    [Abstract] [Full Text] [Related]

  • 20. [Bone following the menopause].
    Peretz A.
    Rev Med Brux; 1995 May 07; 16(4):280-4. PubMed ID: 7481243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.